Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours By Ogkologos - March 2, 2026 309 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PYNNACLE study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR First Prospective Description of Familial EGFR-mutated Lung Cancer August 23, 2023 Many Patients with NSCLC Show Targetable Alterations in the PI3K Pathway March 24, 2021 Aromatase inhibitors cut breast cancer recurrence in younger patients February 11, 2022 Unravelling the mystery of Barrett’s oesophagus October 25, 2021 Load more HOT NEWS Efficacy and Safety of Patritumab Deruxtecan in Patients with EGFR-mutated NSCLC... Biopsia por aspiración con aguja fina (PAAF): Cómo prepararse y qué... 3 Steps to Making the Right Decisions for You During Cancer:... For Children with Neuroblastoma, Trial Results Highlight Continued Evolution of Treatment
